SloveniaA new European Union directive, which came into effect on January 1, 2025, requires pharmaceutical producers and cosmetic manufacturers to cover at least 80% of the costs associated with advanced wastewater treatment technologies. This includes the removal of micro-pollutants such as drug residues and microplastics during the fourth stage of wastewater purification. In Slovenia, the implementation of this directive has raised concerns within the pharmaceutical industry, as they have yet to calculate these costs or determine how they would be distributed among producers. Industry representatives warn that this financial burden could threaten the availability of affordable generic medicines, potentially leading to shortages. The directive aims to address water pollution caused by pharmaceutical residues, particularly antibiotics, which standard treatment systems cannot effectively remove.
Bias read (Center): The article presents the issue objectively, citing concerns from the pharmaceutical industry and explaining the implications of the EU directive without overtly favoring any side. It provides background information on the directive, its requirements, and potential impacts, while quoting industry and
Why these scores (Factual 85 · Objective 60): The article accurately reports that the new EU directive could affect generic medicines by requiring manufacturers to cover 80% of costs for advanced wastewater treatment. It references the Slovenian lack of cost calculation and model, aligning with the primary source. However, it presents this info
